Table 4.
Standardized Incidence Ratios of Selected Second Cancer Risk in Thyroid Cancer Patients by Histology and Year of Diagnosis
| |
Histologic subtypes |
|||||||
|---|---|---|---|---|---|---|---|---|
| |
Papillary |
Follicular |
Medullary |
Anaplastic |
||||
| Site | n | SIR [CI] | n | SIR [CI] | n | SIR [CI] | n | SIR [CI] |
| All sites | 3405 | 1.09 [1.06–1.13] | 764 | 1.06 [0.99–1.14] | 117 | 0.9 [0.74–1.06] | 11 | 1.93 [0.96–3.44] |
| Salivary | 29 | 3.78 [2.53–5.43] | 2 | — | 0 | — | 0 | — |
| Kidney | 161 | 2.26 [1.93–2.64] | 37 | 2.35 [1.65–3.24] | 1 | — | 2 | — |
| Breast | 835 | 1.14 [1.06–1.22] | 153 | 1.07 [0.91–1.25] | 28 | 1.16 [0.77–1.68] | 0 | — |
| Prostate | 385 | 1.26 [1.14–1.39] | 99 | 1.18 [0.96–1.43] | 13 | 0.81 [0.43–1.38] | 1 | — |
| Melanoma of the skin | 164 | 1.31 [1.12–1.53] | 24 | 1.03 [0.66–1.53] | 8 | 1.84 [0.79–3.62] | 1 | — |
| Non-Hodgkin lymphoma | 138 | 1.12 [0.94–1.32] | 27 | 0.97 [0.64–1.41] | 10 | 1.95 [0.94–3.59] | 0 | — |
| Thyroid | 104 | 1.46 [1.19–1.77] | 25 | 2.31 [1.5–3.42] | 8 | 4.44 [1.92–8.74] | 0 | — |
| Leukemia | 106 | 1.48 [1.21–1.78] | 22 | 1.25 [0.78–1.89] | 1 | — | 2 | — |
| Myeloma | 58 | 1.63 [1.24–2.11] | 13 | 1.42 [0.76–2.44] | 2 | — | 0 | — |
| Brain | 52 | 1.46 [1.09–1.92] | 9 | 1.21 [0.55–2.29] | 1 | — | 0 | — |
| |
Year of diagnosis |
|||||||
|---|---|---|---|---|---|---|---|---|
| |
1973–1983 |
1984–1993 |
1994–2003 |
2004–2008 |
||||
| Site | N | SIR [CI] | N | SIR [CI] | N | SIR [CI] | N | SIR [CI] |
| All sites | 1612 | 1.02 [0.97–1.07] | 1375 | 1.03 [0.97–1.08] | 1192 | 1.21 [1.14–1.28] | 278 | 1.45 [1.28–1.62] |
| Salivary | 10 | 2.68 [1.28–4.93] | 4 | — | 11 | 4.37 [2.18–7.83] | 6 | 12.08 [4.43–26.29] |
| Kidney | 77 | 2.37 [1.87–2.96] | 61 | 2.07 [1.58–2.65] | 58 | 2.33 [1.77–3.01] | 17 | 3.13 [1.83–5.02] |
| Breast | 394 | 1.13 [1.02–1.25] | 318 | 1.06 [0.95–1.18] | 280 | 1.21 [1.08–1.37] | 49 | 1.09 [0.81–1.45] |
| Prostate | 163 | 1.09 [0.93–1.27] | 182 | 1.28 [1.1–1.48] | 141 | 1.32 [1.11–1.56] | 25 | 1.21 [0.78–1.78] |
| Melanoma of the skin | 56 | 1.09 [0.82–1.41] | 64 | 1.27 [0.98–1.63] | 61 | 1.34 [1.03–1.73] | 19 | 1.95 [1.18–3.05] |
| Non-Hodgkin lymphoma | 62 | 1.03 [0.79–1.32] | 57 | 1.08 [0.82–1.4] | 58 | 1.44 [1.09–1.86] | 8 | 1.02 [0.44–2] |
| Thyroid | 29 | 1.21 [0.81–1.74] | 43 | 1.63 [1.18–2.2] | 45 | 1.59 [1.16–2.12] | 24 | 3.49 [2.23–5.19] |
| Leukemia | 41 | 1.08 [0.78–1.47] | 35 | 1.13 [0.79–1.57] | 50 | 2.2 [1.63–2.9] | 8 | 1.88 [0.81–3.7] |
| Myeloma | 23 | 1.22 [0.77–1.83] | 25 | 1.61 [1.04–2.38] | 21 | 1.85 [1.14–2.83] | 6 | 2.73 [1–5.93] |
| Brain | 24 | 1.37 [0.87–2.03] | 24 | 1.64 [1.05–2.43] | 13 | 1.16 [0.62–1.98] | 2 | — |